MyFinsight
Home
About
Contact
nams: the income statement
Download
Download image
Total comprehensive
loss for the period,...
-$71,692K
(-330.66%↓ Y/Y)
Unrealized gain/(loss) on
available-for-sale securities, net...
$313K
Loss for the period
-$72,005K
Loss before tax
-$72,005K
(-332.51%↓ Y/Y)
Foreign exchange
gains/(losses)
$218K
(-95.34%↓ Y/Y)
Interest income
$6,713K
(51.09%↑ Y/Y)
Loss on disposal of
property, plant and...
-$1K
Fair value change -
warrants
$23,792K
Operating loss
-$55,143K
(-120.55%↓ Y/Y)
Revenue
$348K
(-98.80%↓ Y/Y)
Total operating
expenses
$55,491K
(2.54%↑ Y/Y)
Selling, general and
administrative expenses
$24,520K
(33.17%↑ Y/Y)
Research and development
expenses
$30,971K
(-13.25%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)